advertisement
11.16 Vehicles, delivery systems, pharmacokinetics, formulation (84)
Showing records 1 to 25
Search within classification 11.16 Vehicles, delivery systems, pharmacokinetics, formulation76819 High Prevalence of Ocular Surface Disease Among Glaucoma Patients in Thailand
Ruangvaravate N
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 387-394
76552 Modulation of Schlemm's canal endothelial cell stiffness via latrunculin loaded block copolymer micelles
Stack T
Journal of Biomedical Materials Research - Part A 2018; 106: 1771-1779
76638 Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye
Wong ABC
Ocular Surface 2018; 16: 289-293
76887 Intraocular light scatter in patients on topical intraocular pressure-lowering medication
Pérez-Bartolomé F
European Journal of Ophthalmology 2018; 0: 1120672117753667
77293 Efficacy of three different formulations of brimonidine for control of intraocular pressure in primary open-angle glaucoma: A 6-week randomized trial
Bhatti A
Oman journal of ophthalmology 2018; 11: 140-143
76857 Sustained Dorzolamide Release Prevents Axonal and Retinal Ganglion Cell Loss in a Rat Model of IOP-Glaucoma
Pitha I
Translational vision science & technology 2018; 7: 13
77022 Exploring gelatin nanoparticles as novel nanocarriers for Timolol Maleate: Augmented in-vivo efficacy and safe histological profile
Shokry M
International Journal of Pharmaceutics 2018; 545: 229-239
76239 Eyelid Changes Related to Meibomian Gland Dysfunction in Early Middle-Aged Patients Using Topical Glaucoma Medications
Kim JH
Cornea 2018; 37: 421-425
76812 Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness
Hommer A
European Journal of Ophthalmology 2018; 28: 385-392
77182 Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride
Wong TT
Clinical and Experimental Ophthalmology 2018; 0:
76990 Prospective, Randomized, Single Masked, Parallel Study Exploring the Effects of a Preservative-Free Ophthalmic Solution Containing Hyaluronic Acid 0.4% and Taurine 0.5% on the Ocular Surface of Glaucoma Patients Under Multiple Long-Term Topical Hypotensiv
Roberti G
Advances in Therapy 2018; 35: 686-696
76188 Drop instillation and glaucoma
Davis SA
Current Opinions in Ophthalmology 2018; 29: 171-177
77020 Co-delivery of timolol and hyaluronic acid from semi-circular ring-implanted contact lenses for the treatment of glaucoma: in vitro and in vivo evaluation
Desai AR
Biomaterials science 2018; 6: 1580-1591
76957 Delivery of therapeutics for deep-seated ocular conditions - status quo
Nguyen H
Journal of Pharmacy and Pharmacology 2018; 70: 994-1001
77208 Evaluating Eye Drop Instillation Technique and Its Determinants in Glaucoma Patients
Gao X
Journal of Ophthalmology 2018; 2018: 1376020
77022 Exploring gelatin nanoparticles as novel nanocarriers for Timolol Maleate: Augmented in-vivo efficacy and safe histological profile
Hathout RM
International Journal of Pharmaceutics 2018; 545: 229-239
77182 Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride
Aung T
Clinical and Experimental Ophthalmology 2018; 0:
76188 Drop instillation and glaucoma
Sleath B
Current Opinions in Ophthalmology 2018; 29: 171-177
76812 Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness
Schmidl D
European Journal of Ophthalmology 2018; 28: 385-392
76957 Delivery of therapeutics for deep-seated ocular conditions - status quo
Eng S
Journal of Pharmacy and Pharmacology 2018; 70: 994-1001
76239 Eyelid Changes Related to Meibomian Gland Dysfunction in Early Middle-Aged Patients Using Topical Glaucoma Medications
Shin YU
Cornea 2018; 37: 421-425
76990 Prospective, Randomized, Single Masked, Parallel Study Exploring the Effects of a Preservative-Free Ophthalmic Solution Containing Hyaluronic Acid 0.4% and Taurine 0.5% on the Ocular Surface of Glaucoma Patients Under Multiple Long-Term Topical Hypotensiv
Agnifili L
Advances in Therapy 2018; 35: 686-696
76638 Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye
Wang MTM
Ocular Surface 2018; 16: 289-293
76887 Intraocular light scatter in patients on topical intraocular pressure-lowering medication
Martínez de la Casa JM
European Journal of Ophthalmology 2018; 0: 1120672117753667
77020 Co-delivery of timolol and hyaluronic acid from semi-circular ring-implanted contact lenses for the treatment of glaucoma: in vitro and in vivo evaluation
Maulvi FA
Biomaterials science 2018; 6: 1580-1591
